SAHPRA Presents Patient-Focused Drug Development at ICMRA
South Africa's medicines regulator outlined its approach to patient involvement at the 2026 ICMRA Summit in Seoul.
Updated on Nov. 18, 2026 in Pets

The South African Health Products Regulatory Authority (SAHPRA) took part in the ICMRA Summit 2026 in Seoul, Republic of Korea. Its CEO, Dr Boitumelo Semete-Makokotlela, presented South Africa's patient-focused drug development approach in Session 3 on 4 November 2026.
Why it matters
ICMRA is a voluntary, executive-level body of medicines regulatory authorities, and the Summit brought together heads of regulators from around 30 countries. Shared discussion of regulatory approaches helps shape how medicines are developed and assessed for South African patients.
The ICMRA Summit and Plenary ran from 3 to 6 November 2026 at the Conrad Seoul, hosted by the Ministry of Food and Drug Safety of the Republic of Korea. Details of any formal decisions reached at the Plenary are not included in the source material.
The players
SAHPRA (South African Health Products Regulatory Authority)
SAHPRA is South Africa's national regulator for medicines and other health products, responsible for their safety, quality and efficacy.
ICMRA (International Coalition of Medicines Regulatory Authorities)
ICMRA is a voluntary coalition of medicines regulatory authorities that works on shared regulatory challenges, with 43 member agencies from 40 countries.
The details
At the Summit, Session 2 addressed the shift from traditional animal testing to new approach methodologies, while Session 3, co-chaired by Poland's URPL and the EMA, featured SAHPRA's presentation. ICMRA also published a statement on the 3Rs of animal testing on 1 October 2026.
Timeline
1 October 2026: ICMRA published its statement on the 3Rs of animal testing.
3 to 6 November 2026: The ICMRA Summit and Plenary were held in Seoul.
4 November 2026: SAHPRA CEO Dr Boitumelo Semete-Makokotlela presented in Session 3.
18 November 2026: SAHPRA published an article on its Summit participation.
Lifestyle Context
The Summit's Session 2 focus on new approach methodologies follows ICMRA's 1 October 2026 statement on the 3Rs of animal testing, reflecting a regulatory move away from animal models that struggle to predict human outcomes. SAHPRA's participation places South Africa within that international shift.
The Summit's focus on patient involvement and new approach methodologies may shape how medicines are tested and approved over time. For South African readers, changes in regulatory practice would apply to the medicines and health products SAHPRA oversees.
The takeaway
Regulators are moving toward methods that better reflect human outcomes and ethical expectations. Readers can follow how South Africa's regulator applies these lessons in its own approvals and patient engagement.
Further reading
For more on how regulatory science is changing animal testing, explore Veterinary Medicine.






